Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety of the Addition of Canagliflozin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sitagliptin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must have a diagnosis of type 2 diabetes mellitus~* Must have a screening HbA1c of \>=7.5% to \<=10.5%~* Must be on metformin \>=1500 mg/day and sitagliptin 100 mg/day (or equivalent fixed dose combination) at a stable dose for at least 12 weeks before screening~Exclusion Criteria:~* History of diabetic ketoacidosis or T1DM, hereditary glucose-galactose malabsorption or primary renal glycosuria~* A myocardial infarction, unstable angina, revascularization procedure or cerebrovascular accident within 12 weeks before screening~* eGFR \<60 ml/min/1.73m2, or serum creatinine \>=1.4 mg/dL for men and \>=1.3 mg/dL for women~* Known significant liver disease (eg, acute hepatitis, chronic active hepatitis, cirrhosis)~* Major surgery (ie, requiring general anesthesia) within 12 weeks before screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Canagliflozin (JNJ-28431754) (Type: EXPERIMENTAL): Each participant will receive canagliflozin (JNJ-28431754) 100 mg once daily during the first 6 weeks, then the dose may be increased to 300 mg once daily.
- Placebo (Type: PLACEBO_COMPARATOR): Each participant will receive placebo (inactive medication) once daily for 28 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).